These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 2855616)
1. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir. Al-Samarai A; Kinghorn G; Potter C Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616 [No Abstract] [Full Text] [Related]
2. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. Chatis PA; Miller CH; Schrager LE; Crumpacker CS N Engl J Med; 1989 Feb; 320(5):297-300. PubMed ID: 2536137 [No Abstract] [Full Text] [Related]
3. [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. Jansen CL; Maris-Tegeler WG; Wertheim-van Dillen PM; Frissen PH; Weiland HT; van der Noordaa J Ned Tijdschr Geneeskd; 1992 Feb; 136(6):280-4. PubMed ID: 1311058 [TBL] [Abstract][Full Text] [Related]
4. The potential of phosphonoformate for the treatment of herpex simplex labialis. Oxford J J Antimicrob Chemother; 1980 Nov; 6(6):694-5. PubMed ID: 6449499 [No Abstract] [Full Text] [Related]
5. Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. Iino T; Gondo H; Ohno Y; Minagawa H; Iwasaki H; Maruyama T; Nakashima H; Niho Y Bone Marrow Transplant; 1996 Dec; 18(6):1185-8. PubMed ID: 8971394 [TBL] [Abstract][Full Text] [Related]
6. Herpes simplex type 1 defective interfering particles do not affect the antiviral activity of acyclovir, foscarnet and adenine arabinoside. Harmenberg JG; Svensson LT Acta Virol; 1988 Mar; 32(2):153-5. PubMed ID: 2899962 [TBL] [Abstract][Full Text] [Related]
7. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569 [TBL] [Abstract][Full Text] [Related]
8. Acyclovir-resistant herpes in AIDS treated with foscarnet. Youle MM; Hawkins DA; Collins P; Shanson DC; Evans R; Oliver N; Lawrence A Lancet; 1988 Aug; 2(8606):341-2. PubMed ID: 2899762 [No Abstract] [Full Text] [Related]
9. [Treatment of cytomegalovirus infections in immunosuppressed patients]. Michon C; Girard PM; Ngovan P; Simonpoli AM; Le Hoang P Ann Med Interne (Paris); 1988; 139(7):511-5. PubMed ID: 2854380 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. Lawee D; Rosenthal D; Aoki FY; Portnoy J CMAJ; 1988 Feb; 138(4):329-33. PubMed ID: 2962712 [TBL] [Abstract][Full Text] [Related]
11. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. Safrin S; Crumpacker C; Chatis P; Davis R; Hafner R; Rush J; Kessler HA; Landry B; Mills J N Engl J Med; 1991 Aug; 325(8):551-5. PubMed ID: 1649971 [TBL] [Abstract][Full Text] [Related]
12. Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS. MacPhail LA; Greenspan D; Schiødt M; Drennan DP; Mills J Oral Surg Oral Med Oral Pathol; 1989 Apr; 67(4):427-32. PubMed ID: 2524706 [TBL] [Abstract][Full Text] [Related]
13. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro]. Thiel KD; Wutzler P; Sprössig M; Bertram D Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963 [No Abstract] [Full Text] [Related]
14. Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. Schmit I; Boivin G J Infect Dis; 1999 Aug; 180(2):487-90. PubMed ID: 10395866 [TBL] [Abstract][Full Text] [Related]
15. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease. Charles SJ; Gray JJ Br J Ophthalmol; 1990 May; 74(5):286-8. PubMed ID: 2162190 [TBL] [Abstract][Full Text] [Related]
16. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Erlich KS; Jacobson MA; Koehler JE; Follansbee SE; Drennan DP; Gooze L; Safrin S; Mills J Ann Intern Med; 1989 May; 110(9):710-3. PubMed ID: 2522751 [TBL] [Abstract][Full Text] [Related]
17. Acyclovir-resistant varicella zoster responsive to foscarnet. Smith KJ; Kahlter DC; Davis C; James WD; Skelton HG; Angritt P Arch Dermatol; 1991 Jul; 127(7):1069-71. PubMed ID: 1648341 [No Abstract] [Full Text] [Related]
18. Foscarnet effective in acyclovir-resistant herpes. Am Pharm; 1991 Nov; NS31(11):12. PubMed ID: 1836936 [No Abstract] [Full Text] [Related]
19. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. Birch CJ; Tachedjian G; Doherty RR; Hayes K; Gust ID J Infect Dis; 1990 Sep; 162(3):731-4. PubMed ID: 2167340 [TBL] [Abstract][Full Text] [Related]
20. [Development of resistance of herpes simplex virus to antivirus drugs in vitro]. Chen ZJ; Liu WG; Song JZ Yao Xue Xue Bao; 1992; 27(1):10-4. PubMed ID: 1382356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]